BRAF Gene and Melanoma: Back to the Future

BRAF Gene and Melanoma: Back to the Future

As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) signalling pathway and its targeting has represented a valuable milestone for the advanced and, more recently, for the completely re...

Full description

Bibliographic Details
Main Authors: Margaret Ottaviano, Emilio Francesco Giunta, Marianna Tortora, Marcello Curvietto, Laura Attademo, Davide Bosso, Cinzia Cardalesi, Mario Rosanova, Pietro De Placido, Erica Pietroluongo, Vittorio Riccio, Brigitta Mucci, Sara Parola, Maria Grazia Vitale, Giovannella Palmieri, Bruno Daniele, Ester Simeone, on behalf of SCITO YOUTH
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
melanoma
BRAF mutation
immunotherapy
targeted therapy
Online Access:https://www.mdpi.com/1422-0067/22/7/3474

Internet

https://www.mdpi.com/1422-0067/22/7/3474

Similar Items